BioSpace News Archive

Todos Medical Ltd. (OTCQB: TOMDF), an in vitro diagnostics company focused on distributing comprehensive solutions for COVID-19 screening and diagnosis, and developing blood tests for the early detection of cancer and Alzheimer’s disease,

LyGenesis, Inc., a biotechnology company focused on regenerative medicine, announced today that four peer-reviewed papers have been published on its organ regeneration technology.

SQI Diagnostics Inc. (“SQI” or the “Company”) (TSX-V: SQD) (OTCQB: SQIDF), a life sciences and diagnostics company that develops and commercializes proprietary technologies and products for advanced microarray diagnostics, today announced that effective August 26, 2020, it has granted (the “Grants”) 1,807,797 stock options

In the US, no standards are enforced for face masks outside of the medical sector, but AEA Group LLC has stepped out to make approved, certified and tested face masks accessible online especially for the public.

North America Frac Sand, Inc. dba Voycare, a telemedicine service provider and Chinese language digital health platform exclusively dedicated to women’s health, is pleased to welcome Xuan Zhou of Fudan University to its Board of Directors.

Parexel, a leading provider of solutions to accelerate the development and delivery of innovative new therapies to improve world health, from Clinical through Commercialization, today announced it has signed a new master service agreement (MSA) with Pfizer Inc.

Lumos Pharma, Inc. (NASDAQ:LUMO), a clinical-stage biopharmaceutical company focused on therapeutics for rare diseases, announced that the company will present and host one-on-one meetings at the following virtual investor conferences to be held in September:

Oncology Pharma, Inc. (OTCPK: ONPH) is pleased to announce that it has extended its Letter of Intent with Kalos Therapeutics.

Akers Biosciences, Inc. (the “Company”) (NASDAQ: AKER), a developer of rapid health information technologies, today announced with its partner, Premas Biotech, positive proof of concept results from Animal Studies conducted during a 4 week test of its SARS-CoV-2 vaccine candidate in mice.

ACTO, the omnichannel education and engagement platform for life sciences, today announced the closing of a $11.5 million Series A round led by Resolve Growth Partners, a Baltimore-based growth equity firm focused on software entrepreneurs